Literature DB >> 25908915

Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.

P Dubé1, L Sideris1, C Law2, L Mack3, E Haase4, C Giacomantonio5, A Govindarajan6, M K Krzyzanowska7, P Major8, Y McConnell9, W Temple3, R Younan10, J A McCart6.   

Abstract

To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved. Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres. The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.

Entities:  

Keywords:  Peritoneal surface malignancy; appendiceal cancer; carcinomatosis; colorectal cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal metastasis; pseudomyxoma peritonei

Year:  2015        PMID: 25908915      PMCID: PMC4399618          DOI: 10.3747/co.22.2058

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  88 in total

1.  Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin.

Authors:  V J Verwaal; F A N Zoetmulder
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

2.  Cytoreduction and HIPEC for peritoneal carcinomatosis from colorectal origin: the Amsterdam experience.

Authors:  V J Verwaal
Journal:  Acta Chir Belg       Date:  2006 May-Jun       Impact factor: 1.090

3.  The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study.

Authors:  Franck Zenasni; Marion Botella; Dominique Elias; Sarah Dauchy; Valérie Boige; David Malka; Michel Ducreux; Jean-Pierre Pignon; Diane Goéré; Marc Pocard
Journal:  Support Care Cancer       Date:  2009-02-06       Impact factor: 3.603

4.  Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors.

Authors:  Konstantinos I Votanopoulos; Douglas S Swords; Katrina R Swett; Reese W Randle; Perry Shen; John H Stewart; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2013-06-26       Impact factor: 5.344

5.  Pathophysiology and biology of peritoneal carcinomatosis.

Authors:  Shigeki Kusamura; Dario Baratti; Nadia Zaffaroni; Raffaella Villa; Barbara Laterza; Maria Rosaria Balestra; Marcello Deraco
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

6.  [Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: cytoreductive surgery and intraperitoneal chemotherapy].

Authors:  O Glehen; E Cotte; C Brigand; C Arvieux; A C Sayag-Beaujard; F N Gilly
Journal:  Rev Med Interne       Date:  2005-10-05       Impact factor: 0.728

Review 7.  [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed].

Authors:  Marc Pocard; Valérie Boige
Journal:  Bull Cancer       Date:  2005-02       Impact factor: 1.276

8.  Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.

Authors:  Vic J Verwaal; Henk Boot; Berthe M P Aleman; Harm van Tinteren; Frans A N Zoetmulder
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

9.  Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases.

Authors:  Joseph Misdraji; Rhonda K Yantiss; Fiona M Graeme-Cook; Ulysses J Balis; Robert H Young
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

10.  Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  V J Verwaal; H van Tinteren; S van Ruth; F A N Zoetmulder
Journal:  Br J Surg       Date:  2004-06       Impact factor: 6.939

View more
  15 in total

1.  The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.

Authors:  Alexandre Brind'Amour; Mitchell Webb; Marina Parapini; Lucas Sidéris; Maja Segedi; Stephen W Chung; Stéphanie Chartier-Plante; Pierre Dubé; Charles H Scudamore; Peter T W Kim
Journal:  Clin Exp Metastasis       Date:  2021-01-24       Impact factor: 5.150

2.  Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.

Authors:  R C Auer; D Sivajohanathan; J Biagi; J Conner; E Kennedy; T May
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

3.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

4.  The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases.

Authors:  Aditi Bhatt; Sanket Mehta; Ramakrishnan Ayloor Seshadri; Kayomarz Sethna; Shabber Zaveri; Firoz Rajan; Vikas Mahajan; Shivendra Singh; E Hemanth Raj; Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2016-02-02

5.  Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study

Authors:  Evan Jost; Lloyd A. Mack; Lucas Sideris; Pierre Dube; Walley Temple; Antoine Bouchard-Fortier
Journal:  Can J Surg       Date:  2020-02-21       Impact factor: 2.089

6.  Adenocarcinoma of the Colon Disguised as Abdominal Wall Abscess: Case Report and Review of the Literature.

Authors:  L Attar; N Trabulsi; A A Maghrabi; M Nassif
Journal:  Case Rep Surg       Date:  2018-01-24

7.  Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.

Authors:  Nina R Sluiter; Koen P Rovers; Youssra Salhi; Stijn L Vlek; Veerle M H Coupé; Henk M W Verheul; Geert Kazemier; Ignace H J T de Hingh; Jurriaan B Tuynman
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

8.  Curative versus palliative treatments for colorectal cancer with peritoneal carcinomatosis: a systematic review and meta-analysis.

Authors:  Wenqiong Wu; Shipeng Yan; Xianzhen Liao; Haifang Xiao; Zhongxi Fu; Lizhang Chen; Jinsong Mou; Haibo Yu; Lian Zhao; Xiangguo Liu
Journal:  Oncotarget       Date:  2017-10-20

9.  ASO Author Reflections: Toward Improved Selection of Patients for Cytoreduction and HIPEC: Identification of Prognostic Factors for Patients with Colorectal Peritoneal Metastases.

Authors:  Nina R Sluiter; Jurriaan B Tuynman
Journal:  Ann Surg Oncol       Date:  2018-10-09       Impact factor: 5.344

Review 10.  Anesthetic implications in hyperthermic intraperitoneal chemotherapy.

Authors:  Nishkarsh Gupta; Vinod Kumar; Rakesh Garg; Sachidanand Jee Bharti; Seema Mishra; Sushma Bhatnagar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.